Literature DB >> 28289945

A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome.

Hebert Alberto Vargas1, Harini Veeraraghavan2, Maura Micco3, Stephanie Nougaret3,4,5, Yulia Lakhman3, Andreas A Meier3, Ramon Sosa3, Robert A Soslow6, Douglas A Levine7, Britta Weigelt6, Carol Aghajanian8, Hedvig Hricak3, Joseph Deasy2, Alexandra Snyder8, Evis Sala3.   

Abstract

PURPOSE: To evaluate the associations between clinical outcomes and radiomics-derived inter-site spatial heterogeneity metrics across multiple metastatic lesions on CT in patients with high-grade serous ovarian cancer (HGSOC).
METHODS: IRB-approved retrospective study of 38 HGSOC patients. All sites of suspected HGSOC involvement on preoperative CT were manually segmented. Gray-level correlation matrix-based textures were computed from each tumour site, and grouped into five clusters using a Gaussian Mixture Model. Pairwise inter-site similarities were computed, generating an inter-site similarity matrix (ISM). Inter-site texture heterogeneity metrics were computed from the ISM and compared to clinical outcomes.
RESULTS: Of the 12 inter-site texture heterogeneity metrics evaluated, those capturing the differences in texture similarities across sites were associated with shorter overall survival (inter-site similarity entropy, similarity level cluster shade, and inter-site similarity level cluster prominence; p ≤ 0.05) and incomplete surgical resection (similarity level cluster shade, inter-site similarity level cluster prominence and inter-site cluster variance; p ≤ 0.05). Neither the total number of disease sites per patient nor the overall tumour volume per patient was associated with overall survival. Amplification of 19q12 involving cyclin E1 gene (CCNE1) predominantly occurred in patients with more heterogeneous inter-site textures.
CONCLUSION: Quantitative metrics non-invasively capturing spatial inter-site heterogeneity may predict outcomes in patients with HGSOC. KEY POINTS: • Calculating inter-site texture-based heterogeneity metrics was feasible • Metrics capturing texture similarities across HGSOC sites were associated with overall survival • Heterogeneity metrics were also associated with incomplete surgical resection of HGSOC.

Entities:  

Keywords:  Ovarian cancer; Radiogenomics; Radiomics; Survival; Texture

Mesh:

Substances:

Year:  2017        PMID: 28289945      PMCID: PMC5545058          DOI: 10.1007/s00330-017-4779-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  20 in total

1.  Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate.

Authors:  J Engel; R Eckel; G Schubert-Fritschle; J Kerr; W Kuhn; J Diebold; R Kimmig; J Rehbock; D Hölzel
Journal:  Eur J Cancer       Date:  2002-12       Impact factor: 9.162

Review 2.  Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.

Authors:  Lorenza Mittempergher
Journal:  Curr Oncol Rep       Date:  2016-07       Impact factor: 5.075

3.  Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.

Authors:  David M Hyman; Qin Zhou; Alexia Iasonos; Rachel N Grisham; Angela G Arnold; Mary F Phillips; Jasmine Bhatia; Douglas A Levine; Carol Aghajanian; Kenneth Offit; Richard R Barakat; David R Spriggs; Noah D Kauff
Journal:  Cancer       Date:  2011-12-02       Impact factor: 6.860

4.  Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study.

Authors:  Hebert Alberto Vargas; Maura Miccò; Seong Im Hong; Debra A Goldman; Fanny Dao; Britta Weigelt; Robert A Soslow; Hedvig Hricak; Douglas A Levine; Evis Sala
Journal:  Radiology       Date:  2014-11-10       Impact factor: 11.105

5.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

6.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

7.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Authors:  Willy Hugo; Jesse M Zaretsky; Lu Sun; Chunying Song; Blanca Homet Moreno; Siwen Hu-Lieskovan; Beata Berent-Maoz; Jia Pang; Bartosz Chmielowski; Grace Cherry; Elizabeth Seja; Shirley Lomeli; Xiangju Kong; Mark C Kelley; Jeffrey A Sosman; Douglas B Johnson; Antoni Ribas; Roger S Lo
Journal:  Cell       Date:  2016-03-17       Impact factor: 41.582

8.  Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.

Authors:  Dariush Etemadmoghadam; Anna deFazio; Rameen Beroukhim; Craig Mermel; Joshy George; Gad Getz; Richard Tothill; Aikou Okamoto; Maria B Raeder; Paul Harnett; Stephen Lade; Lars A Akslen; Anna V Tinker; Bianca Locandro; Kathryn Alsop; Yoke-Eng Chiew; Nadia Traficante; Sian Fereday; Daryl Johnson; Stephen Fox; William Sellers; Mitsuyoshi Urashima; Helga B Salvesen; Matthew Meyerson; David Bowtell
Journal:  Clin Cancer Res       Date:  2009-02-03       Impact factor: 12.531

9.  Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

Authors:  Dejan Juric; Pau Castel; Malachi Griffith; Obi L Griffith; Helen H Won; Haley Ellis; Saya H Ebbesen; Benjamin J Ainscough; Avinash Ramu; Gopa Iyer; Ronak H Shah; Tiffany Huynh; Mari Mino-Kenudson; Dennis Sgroi; Steven Isakoff; Ashraf Thabet; Leila Elamine; David B Solit; Scott W Lowe; Cornelia Quadt; Malte Peters; Adnan Derti; Robert Schegel; Alan Huang; Elaine R Mardis; Michael F Berger; José Baselga; Maurizio Scaltriti
Journal:  Nature       Date:  2014-11-17       Impact factor: 49.962

10.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.

Authors:  Hugo J W L Aerts; Emmanuel Rios Velazquez; Ralph T H Leijenaar; Chintan Parmar; Patrick Grossmann; Sara Carvalho; Sara Cavalho; Johan Bussink; René Monshouwer; Benjamin Haibe-Kains; Derek Rietveld; Frank Hoebers; Michelle M Rietbergen; C René Leemans; Andre Dekker; John Quackenbush; Robert J Gillies; Philippe Lambin
Journal:  Nat Commun       Date:  2014-06-03       Impact factor: 14.919

View more
  35 in total

1.  Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months.

Authors:  Stefania Rizzo; Francesca Botta; Sara Raimondi; Daniela Origgi; Valentina Buscarino; Anna Colarieti; Federica Tomao; Giovanni Aletti; Vanna Zanagnolo; Maria Del Grande; Nicoletta Colombo; Massimo Bellomi
Journal:  Eur Radiol       Date:  2018-05-08       Impact factor: 5.315

2.  Why imaging data alone is not enough: AI-based integration of imaging, omics, and clinical data.

Authors:  Andreas Holzinger; Benjamin Haibe-Kains; Igor Jurisica
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-15       Impact factor: 9.236

3.  CT texture analysis in histological classification of epithelial ovarian carcinoma.

Authors:  He An; Yiang Wang; Esther M F Wong; Shanshan Lyu; Lujun Han; Jose A U Perucho; Peng Cao; Elaine Y P Lee
Journal:  Eur Radiol       Date:  2021-01-06       Impact factor: 5.315

Review 4.  Translational Radiomics: Defining the Strategy Pipeline and Considerations for Application-Part 1: From Methodology to Clinical Implementation.

Authors:  Faiq Shaikh; Benjamin Franc; Erastus Allen; Evis Sala; Omer Awan; Kenneth Hendrata; Safwan Halabi; Sohaib Mohiuddin; Sana Malik; Dexter Hadley; Rasu Shrestha
Journal:  J Am Coll Radiol       Date:  2018-02-01       Impact factor: 5.532

5.  MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy.

Authors:  Natally Horvat; Harini Veeraraghavan; Monika Khan; Ivana Blazic; Junting Zheng; Marinela Capanu; Evis Sala; Julio Garcia-Aguilar; Marc J Gollub; Iva Petkovska
Journal:  Radiology       Date:  2018-03-07       Impact factor: 11.105

6.  Decoding incidental ovarian lesions: use of texture analysis and machine learning for characterization and detection of malignancy.

Authors:  Hyesun Park; Lei Qin; Pamela Guerra; Camden P Bay; Atul B Shinagare
Journal:  Abdom Radiol (NY)       Date:  2020-07-29

7.  Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer.

Authors:  Andreas Meier; Harini Veeraraghavan; Stephanie Nougaret; Yulia Lakhman; Ramon Sosa; Robert A Soslow; Elizabeth J Sutton; Hedvig Hricak; Evis Sala; Hebert A Vargas
Journal:  Abdom Radiol (NY)       Date:  2019-06

Review 8.  Background, current role, and potential applications of radiogenomics.

Authors:  Katja Pinker; Fuki Shitano; Evis Sala; Richard K Do; Robert J Young; Andreas G Wibmer; Hedvig Hricak; Elizabeth J Sutton; Elizabeth A Morris
Journal:  J Magn Reson Imaging       Date:  2017-11-02       Impact factor: 4.813

9.  Noninvasive prediction of residual disease for advanced high-grade serous ovarian carcinoma by MRI-based radiomic-clinical nomogram.

Authors:  Haiming Li; Rui Zhang; Ruimin Li; Wei Xia; Xiaojun Chen; Jiayi Zhang; Songqi Cai; Yong'ai Li; Shuhui Zhao; Jinwei Qiang; Weijun Peng; Yajia Gu; Xin Gao
Journal:  Eur Radiol       Date:  2021-04-16       Impact factor: 5.315

10.  Evaluating the added benefit of CT texture analysis on conventional CT analysis to differentiate benign ovarian cysts.

Authors:  Minkook Seo; Moon Hyung Department Of Radiology Eunpyeong St Mary's Hospital College Of Medicine The Catholic University Of Korea Seoul Republic Of Korea Catholic Smart Imaging Center Eunpyeong St Mary's Hospital College Of Medicine The Catholic University Of Korea Seoul Republic Of Korea Choi; Young Joon Lee; Seung Eun Jung; Sung Eun Rha
Journal:  Diagn Interv Radiol       Date:  2021-07       Impact factor: 2.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.